These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8756403)

  • 1. [Treatment of infectious complications affecting the skin and soft tissues with cefpodoxime proxetil].
    Vyhnánek F; Lochmann O
    Epidemiol Mikrobiol Imunol; 1996 May; 45(2):68-70. PubMed ID: 8756403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiological and clinical studies on cefpodoxime proxetil for bacterial skin and soft tissue infections in pediatric patients.
    Ito K; Ito M
    J Chemother; 1995 Nov; 7 Suppl 4():124-6. PubMed ID: 8904131
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical evaluation of cefpodoxime proxetil in patients with dermatological infections.
    Imaizumi T; Ishikawa H; Hashimoto I
    J Chemother; 1995 Nov; 7 Suppl 4():137-41. PubMed ID: 8904135
    [No Abstract]   [Full Text] [Related]  

  • 4. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of cefpodoxime proxetil on the treatment of bacterial infections].
    Li JT; Hou J; Kao L
    Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):440-3. PubMed ID: 7867436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.
    Stevens DL; Pien F; Drehobl M
    Diagn Microbiol Infect Dis; 1993 Feb; 16(2):123-9. PubMed ID: 8467623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of cefpodoxime proxetil dry syrup in pediatric cutaneous bacterial infection.
    Terui T; Tagami H
    J Chemother; 1995 Nov; 7 Suppl 4():119-21. PubMed ID: 8904129
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice].
    Brambilla C; Benhamou D; Guérin JC; Kelkel E; Muir JF; Prud'homme A; Taytard A; Fauche A
    Pathol Biol (Paris); 1995 Nov; 43(9):815-24. PubMed ID: 8746104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cefpodoxime proxetil dry syrup in pediatric patients with various infections.
    Muranaka H; Yokoyama M
    J Chemother; 1995 Nov; 7 Suppl 4():127-30. PubMed ID: 8904132
    [No Abstract]   [Full Text] [Related]  

  • 10. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefpodoxime proxetil in the treatment of skin and soft tissue infections.
    Tack KJ; Wilks NE; Semerdjian G; Frazier CH; Shirin K; Puopolo A; Crossland SG; Goffe BS; Millikan L
    Drugs; 1991; 42 Suppl 3():51-6. PubMed ID: 1726208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-institutional study on clinical effectiveness of cefpodoxime proxetil dry syrup in childhood infections.
    Imanaka H; Kitahara T; Yoshinaga M; Miyata K
    J Chemother; 1995 Nov; 7 Suppl 4():131-3. PubMed ID: 8904133
    [No Abstract]   [Full Text] [Related]  

  • 13. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Frampton JE; Brogden RN; Langtry HD; Buckley MM
    Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-a-day therapy of cefpodoxime proxetil for respiratory tract infections.
    Sawae Y; Ninomiya K; Sumida I; Inoue T; Takaki K; Okada K; Kumagai Y; Ishimaru T; Shimono N; Misumi H
    J Chemother; 1995 Nov; 7 Suppl 4():134-6. PubMed ID: 8904134
    [No Abstract]   [Full Text] [Related]  

  • 15. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
    Cox CE; Graveline JF; Luongo JM
    Drugs; 1991; 42 Suppl 3():41-50. PubMed ID: 1726207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil.
    Hendrickson JR; North DS
    Ann Pharmacother; 1995 Jun; 29(6):561-5. PubMed ID: 7663025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine.
    Kees F; Wellenhofer M; Bröhl K; Grobecker H
    Arzneimittelforschung; 1996 Apr; 46(4):435-8. PubMed ID: 8740095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials of cefpodoxime proxetil suspension in paediatrics.
    Fujii R
    Drugs; 1991; 42 Suppl 3():57-60. PubMed ID: 1726209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cefpodoxime proxetil with cefaclor in the treatment of sinusitis.
    Gehanno P; Depondt J; Barry B; Simonet M; Dewever H
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():87-91. PubMed ID: 2127269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Respiratory tract infections in general practice. Cefpodoxime proxetil in patients with risk factors and concomitant illnesses].
    Kardos P; Wiese K
    MMW Fortschr Med; 2000 Feb; 142(5):41. PubMed ID: 10715939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.